Physician profile
Brooke Caldwell
NPI 1043785744
$2,347.49
in general payments reported to CMS, 2019-2025
30 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $828 · 2022: $732 · 2023: $104 · 2024: $393 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $246.50 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $233.71 | 2021-2022 | |
| Amgen INC. | $230.42 | 2021-2024 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $162.17 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $132.34 | 2024 | Benlysta |
| Amarin Pharma, INC. | $127.35 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.31 | 2024 | Entyvio |
| Abbvie INC. | $92.66 | 2021-2022 | |
| Argenx US, INC. | $92.34 | 2025 | Vyvgart |
| Horizon Therapeutics Plc | $89.01 | 2023 | Tepezza |
| Merck Sharp & Dohme LLC | $86.89 | 2021-2022 | |
| Novo Nordisk INC | $86.50 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $82.67 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.50 | 2021-2022 | |
| Mannkind Corporation | $63.09 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $56.56 | 2021-2022 | |
| Lilly USA, LLC | $49.31 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $48.49 | 2021-2022 | |
| Antares Pharma, INC. | $42.47 | 2022 | |
| Getinge USA Sales, LLC | $36.94 | 2025 | Maquet Powerled II |
| Boston Scientific Corporation | $30.03 | 2023-2024 | |
| Zealand Pharma US, INC. | $22.37 | 2022 | |
| Esperion Therapeutics, INC. | $21.90 | 2022 | |
| Octapharma USA, INC. | $20.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.28 | 2021 | |
| Dexcom, INC. | $16.22 | 2022 | |
| Tandem Diabetes Care, INC. | $15.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.76 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.54 | 2022 | |
| Radius Health, INC. | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Caldwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.